Sept. 9 – Pfizer’s going before an FDA panel today to try to win approval of a bone drug that’s already been rejected twice. The drug, called Fablyn, is in the same class as Eli Lilly’s osteoporosis drug Evista. Wall Street Journal blogs (free content). Wall Street Journal.